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Inherited mutations in the folliculin (FLCN) gene cause the Birt–Hogg–Dube´ syndrome of familial hair follicle
tumours (fibrofolliculomas), lung cysts and kidney tumours. Though folliculin has features of a tumour sup-
pressor, the precise function of the FLCN gene product is not well characterized. We identified plakophilin-4
(p0071) as a potential novel folliculin interacting protein by yeast two-hybrid analysis. We confirmed the inter-
action of folliculin with p0071 by co-immunoprecipitation studies and, in view of previous studies linking
p0071 to the regulation of rho-signalling, cytokinesis and intercellular junction formation, we investigated
the effect of cell folliculin status on p0071-related functions. Folliculin and p0071 partially co-localized at
cell junctions and in mitotic cells, at the midbody during cytokinesis. Previously, p0071 has been reported
to regulate RhoA signalling during cytokinesis and we found that folliculin deficiency was associated with
increased expression and activity of RhoA and evidence of disordered cytokinesis. Treatment of folliculin-de-
ficient cells with a downstream inhibitor of RhoA signalling (the ROCK inhibitor Y-27632) reversed the
increased cell migration phenotype observed in folliculin-deficient cells. Deficiency of folliculin and of
p0071 resulted in tight junction defects and mislocalization of E-cadherin in mouse inner medullary collecting
duct-3 renal tubular cells. These findings suggest that aspects of folliculin tumour suppressor function are
linked to interaction with p0071 and the regulation of RhoA signalling.
INTRODUCTION
Germline mutations in the folliculin (FLCN) gene cause Birt
Hogg Dube´ (BHD) syndrome, an inherited cancer predispos-
ition disorder, characterized by benign tumours of the hair
follicles (fibrofolliculomas) on the face and upper torso,
renal cell carcinoma (RCC) and lung cysts and pneumothorax
(1,2). In addition, an increased risk of colonic polyps and
cancers has been described in a subset of BHD syndrome
families (3–5). The FLCN gene, mapped to chromosome
17p11.2, is a tumour suppressor gene and biallelic FLCN in-
activation has been described in RCC from patients with BHD
syndrome (6,7). Germline FLCN mutations have also been
described in patients with inherited RCC and familial spon-
taneous pneumothorax (8,9). FLCN encodes a 64 kDa
protein, folliculin (FLCN), which has no significant homology
to other known proteins and is highly conserved throughout
evolution.
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Elucidation of the molecular functions of folliculin is critic-
al for understanding the role of FLCN inactivation in neoplasia
and for developing novel therapeutic strategies for BHD
syndrome. Currently, however, the functions of the FLCN
gene product are poorly understood. Folliculin, through its C
terminus, has been reported to bind two relatively uncharacter-
ized proteins, FNIP1 and FNIP2, and to indirectly interact with
AMPK (AMP-activated protein kinase), thus linking folliculin
to mammalian target of rapamycin (mTOR) signalling (10,11).
However, the precise role of folliculin in the regulation
of mTOR signalling is still under debate as although a follicu-
lin null cell line derived from a BHD patient and FLCN
knockout mice demonstrated up-regulation of mTOR signal-
ling (10,12,13), other reports have suggested a more
complex, context-dependent effect on mTOR activity (14,15).
Folliculin has also been reported to play a role in regulating
transforming growth factor beta signalling (16,17) and in-
crease hypoxia inducible factor transcriptional activity (18),
although the molecular mechanisms for these effects have
not been elucidated.
We investigated whether the identification of novel
folliculin-interacting proteins might provide insights into the
mechanisms of folliculin tumour suppressor activity. We per-
formed a yeast two-hybrid screen with a full-length folliculin
as bait and identified plakophilin-4 (PKP4, p0071) as a candi-
date novel interactor. Previously, p0071 has been linked to the
regulation of Rho-signalling, cytokinesis and intercellular
junction formation, and we proceeded to investigate whether
folliculin could also regulate these functions.
RESULTS
P0071 and FLCN interact in vitro
p0071 (PKP4) was detected as a potential interacting partner
of folliculin in a yeast two-hybrid screen using full-length fol-
liculin as a bait against a human foetal brain cDNA library.
Four independent clones mapping to exons 7–10 of p0071
were identified and p0071 was one of the seven potential inter-
actors detected more than once. To confirm the yeast two-
hybrid results which suggested a direct interaction between
p0071 and folliculin, co-immunoprecipitation studies were
undertaken to confirm the interaction in vitro. p0071
co-immunoprecipitated with folliculin in Hek293 cells trans-
fected with Flag-FLCN (Fig. 1A) and also with endogenous
folliculin in untransfected cells (Fig. 1C). Similarly, when
p0071 was pulled down, folliculin was also detected by im-
munoblotting (Fig. 1B and C). Immunoprecipitation with
control antibody produced no visible FLCN or p0071 signal.
Co-immunoprecipitation was also confirmed in the kidney
cancer cell line (ACHN) (data not shown).
p0071 and FLCN co-localize and interact at cell junctions
during interphase
To identify the cellular context of the FLCN and p0071 inter-
action, we investigated the intracellular localization of both pro-
teins using immunofluorescence microscopic analysis. Interphase
breast cancer cell line-7 (MCF-7), co-transfected with Flag-
tagged FLCN and dsRed-tagged p0071 showed a co-localization
of folliculin and p0071 at cell contacts and also a more disperse
co-localization pattern throughout the cytoplasm (Fig. 2A). The
co-localization at cell junctions was also observed at endogenous
levels in MCF-7 cells, although the pattern of folliculin signal is
more consistent with a transient role for folliculin at cell junc-
tions rather than as a major structural component (Fig. 2B).
Bimolecular fluorescence complementation (BiFC) analysis con-
firmed the association between folliculin and p0071 in living
cells (Hela), with evidence of a strong interaction at cell junctions
and also at regions within the cytoplasm (Fig. 2C).
p0071 and FLCN co-localize and interact at the midbody
during cytokinesis
p0071 localization is reported to differ depending on the cell
cycle stage, with a cell junctional localization in the interphase
cell, differing in mitotic cells when p0071 becomes localized
in the midzone region in anaphase and telophase, then
tightly localized at the midbody during cytokinesis (19). We
hypothesized that folliculin may also interact with p0071 at
these regions in mitotic cells. FTC-133 cells stably transfected
with folliculin were fixed and stained for folliculin, p0071 and
a-tubulin (to identify cells in the late stages of mitosis). A
co-localization pattern of folliculin and p0071 was observed
at the midbody during cytokinesis (Fig. 3A). A concentrated
folliculin and p0071 staining at the midbody was also
observed at endogenous levels in HaCat cells (Fig. 3B).
Using BiFC analysis, we observed a direct interaction of folli-
culin and p0071 by BiFC at the midzone during late telophase/
cytokinesis in Hela cells (Fig. 3C).
Loss of FLCN deregulates RhoA signalling/activity
Previously, p0071 has been reported to regulate RhoA signal-
ling during cytokinesis by binding to RhoA and also Ect2, a
Rho guanine exchange factor (GEF) essential for cytokinesis.
We postulated that as folliculin interacts with p0071 at cell junc-
tions and during cytokinesis, it might also impinge upon RhoA
signalling. Comparison of paired isogenic cell lines demon-
strated that folliculin deficiency was associated with increased
expression of RhoA (Fig. 4A). In the ACHN cell line, levels
of folliculin knockdown by stable shRNA were inversely corre-
lated with RhoA levels in a dose-dependent manner.
RhoA is a small GTPase which is inactive when bound to
guanosine diphosphate (GDP) and is converted to its active
guanosine triphosphate (GTP) bound from when catalysed
by RhoGTPase-specific guanine nucleotide exchange factors
(Rho GEF’s). Conversion back to the GDP bound, inactive
form is stimulated by Rho-specific GTPase activating proteins.
To test if folliculin status influenced cellular RhoA activity,
we used the G-LISA RhoA activation assay to determine the
levels of GTP-bound RhoA in folliculin expressing and
folliculin-deficient cells. In the FTC-133 cell line, the levels
of active RhoA were significantly higher (.2-fold increase)
in folliculin-deficient cells than in those in which folliculin
had been re-expressed (Fig. 4B). Stable knockdown of
FLCN in ACHN cells also caused a significant increase in
RhoA activation (30%; Fig. 4C).
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Loss of FLCN causes cytokinesis defects resulting
in multinucleation
Previously, depletion of p0071 had been reported to causes
severe cytokinesis defects and to induce a multinucleation
phenotype (19). These effects were correlated with deregula-
tion of RhoA signalling during cytokinesis. As we had found
that loss of folliculin increased flux through RhoA signalling,
we investigated if folliculin loss influenced levels of multinu-
cleation in our cellular models. In the folliculin-deficient
FTC-133 cell line, .16% of cells were found to be multinu-
cleated but the reintroduction of folliculin in the FTC-133
cell line significantly reduced this number to 2% multinu-
cleated cells (P, 0.005), indicating that folliculin is required
for cells to complete cytokinesis correctly (Fig. 5).
Reintroduction of FLCN into null metastatic cells
ameliorates the migratory phenotype
Altered expression and activity of RhoA has been previously
shown to correlate with a number of metastatic diseases
(20,21). In FTC-133 cell lines (which are derived from a meta-
static thyroid carcinoma), folliculin inactivation was asso-
ciated with increased RhoA expression and activity (Fig. 4).
We hypothesized that this increased RhoA activity might be
associated with a more migratory phenotype. This was inves-
tigated by a wound healing assay, in which folliculin expres-
sing FTC-133 cells migrated significantly more slowly than
folliculin-deficient (empty vector expressing) cells (P ,
0.05; Fig. 6A and C). The Rho-associated kinases (ROCK 1
and ROCK 2) function downstream of RhoA and can be spe-
cifically targeted by the compound Y-27632, a well-
characterized ROCK inhibitor (22). We postulated that inhibit-
ing signalling downstream of RhoA in folliculin-deficient
FTC-133 cells might ameliorate the migratory phenotype
and phenocopy the re-expression of folliculin. Addition of
10 mM Y-27632 every 12 h significantly reduced the migratory
ability of the cells (P , 0.005; Fig. 6B and C).
Similarly, when tested in a Boyden chamber, folliculin
expressing FTC-133 cells migrated towards a chemotactic
stimulus [fetal bovine serum (FBS)] significantly more
slowly than those null for folliculin (P, 0.02) and treatment
of folliculin null FTC-133 cells with Y-27632 significantly
inhibited cell migration (P, 0.01; Fig. 6D).
Both knockdown of folliculin and p0071 disrupt cell
junctional formation
To investigate the functional impact of the interaction between
FLCN and p0071 at cell junctions, we used the polarized, renal
epithelial cell line mouse inner medullary collecting duct-3
(IMCD-3), cultured on Transwell permeable supports.
siRNA oligonucleotides designed for p0071 and FLCN,
produced 55 and 46% transient knockdown, respectively, at
day 4, tested by quantitative real-time polymerase chain reac-
tion (PCR) (Fig. 7A). Trans-epithelial electrical resistance
(TEER) experiments were carried out at day 8 to test
whether the knockdown of FLCN or p0071 affected the integ-
rity of the cell monolayer. Cells treated with either FLCN or
p0071 siRNA showed significantly reduced TEER at day 8
(FLCN knockdown, 52.5% residual TEER P ¼ 0.004; p0071
knockdown, 72.1% residual TEER, P ¼ 0.005), suggesting a
delay in tight junction formation (Fig. 7B). To investigate the
cause of the reduction in TEER, the cells were stained for a
number of cell junctional proteins. Claudin-1 (tight-junction
component) staining was reduced and disordered in both
FLCN and p0071 knockdown cells, as was E-cadherin (adherens
junction component; Fig. 7C). However, no abnormality was
detected for either knockdown in the staining pattern of ZO-1
(Supplementary Material, Fig. S1), which is located on the cyto-
plasmic surface of intercellular tight junctions. In addition,
IMCD3 cells treated with either FLCN or luciferase (control)
siRNA were grown for 4 days in 2% Geltrex (Invitrogen,
UK). Cells treated with FLCN siRNA displayed a significantly
larger number of incorrectly formed colonies (the absence of a
lumen or multilayered structures, P, 0.0001; Fig. 8).
DISCUSSION
To further elucidate the mechanisms of folliculin tumour sup-
pression, we undertook a yeast two-hybrid screen and identi-
fied PKP4 (p0071) as a potential folliculin interacting
protein. p0071 is a member of the armadillo superfamily and
is part of a subtype of armadillo proteins of which p120ctn
is the prototype. p120ctn proteins include p0071, d-catenin,
ARCF (armadillo repeat protein deleted in velo-cardio-facial
syndrome) and the more distantly related PKP1–3. The char-
acteristic armadillo-repeat domain shared by p120 family pro-
teins is crucial in the interaction of p120 proteins with
classical type I and II cadherins, resulting in the stabilization
of cadherins at membrane adherens junctions (23). p0071
Figure 1. FLCN and p0071 interact in vitro: flag-tagged FLCN was stably
transfected into Hek293 cells. Cell lysates were immunoprecipitated (IP)
with Flag (A) or p0071 (B) and blotted with Flag and p0071. (C) Endogenous
interaction was confirmed in Hek293 parental cells. Lysates were IP with
FLCN, p0071 or control IgG and blotted for p0071 and FLCN. In both IP’s
p0071 and FLCN together, there was no pull down with control IgG.
Arrows indicated the size of bands (kDa).
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has also been shown to bind desmosomal proteins (desmocol-
lin 3a, plakoglobin and desmoplakin) (24,25). In addition, this
family of proteins are multifunctional, also displaying cyto-
plasmic and nuclear localization and a signalling function as
well as their well-characterized role in cell–cell contacts.
Recent studies have provided insights into the range of
p0071 functions and demonstrated a role for p0071 in regulat-
ing Rho signalling during cytokinesis (19). p0071 localizes at
the centrosomes and cell junctions during interphase, however
during mitosis, the protein localizes at the spindle poles until
anaphase becoming focused at the midbody during cytokinesis
(the last step of mitosis) (26). Both loss and overexpression of
p0071 result in defects in cytokinesis that correlate with de-
regulation of RhoA signalling (through an interaction between
both proteins and the Rho GEF Ect2) (19). To determine
whether there was an association between FLCN and PKP4
transcript expression in renal tumours from patients with
BHD syndrome, we interrogated gene expression in six BHD
tumours reported previously by Klomp et al. (27). This
demonstrated that PKP4 expression was significantly down-
regulated in BHD renal tumours (20.536-fold change, P ¼
0.007).
The interaction between folliculin and p0071 was confirmed
in vitro at both exogenous and endogenous levels by
co-immunoprecipitation. The smallest region covered by all
clones of p0071, which were identified in the yeast two-hybrid
screen is from amino acids 374 to 493, representing a section
of the head domain which likely binds folliculin (early indica-
tions by deletion mapping suggest this finding to be accurate).
We proceeded to define the cellular context of the folliculin/
p0071 interaction by performing comprehensive immunofluor-
escence analysis using a number of different cell lines. When
both proteins were overexpressed, co-localization was clearly
observed at cell–cell contacts and at regions throughout
the cytoplasm. By re-expressing FLCN in FTC-133 cells (no
endogenous expression of FLCN), we observed tight co-
localization of Flag-tagged FLCN and endogenous p0071 at
the midbody in dividing cells. Similarly, co-localization was
Figure 2. p0071 and folliculin are co-localized and interact at cell–cell junctions. (A) MCF-7 cells were co-transfected with flag-tagged FLCN and dsRed-tagged
p0071, fixed and stained for Flag and 4′,6-diamidino-2-phenylindole (DAPI). Folliculin and p0071 co-localize at cell junctions and in a disperse pattern at certain
points within the cytoplasm. Manders overlap co-efficient ¼ 0.968. (B) Confluent MCF-7 cells were fixed and stained for endogenous folliculin and p0071. Both
p0071 and FLCN localized to cell junctions displaying a co-localized pattern. FLCN and p0071 co-localized pixels were identified using ImageJ software and are
displayed in white on the zoomed images. Manders overlap co-efficient ¼ 0.599. (C) BiFC analysis was used to confirm/identify the location of the interaction
between FLCN and p0071 in living cells. Hela cells co-expressed with pVen-1-Flag-p0071 and pVen2-HA-FLCN display a clear BiFC signal at cell junctions
and throughout the cytoplasm.
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clearly visible at cell contacts and at the midbody in the
mitotic cell, by endogenous staining of p0071 and FLCN.
BiFC analysis for which folliculin and p0071 was fused to
separate halves of yellow fluorescent protein (YFP) and
co-expressed in Hela cells, demonstrated a folliculin/p0071
interaction at both cell junctions and also a concentrated
BiFC signal between dividing cells during late telophase/
cytokinesis.
Disordered cytokinesis is a frequent feature of human
cancers and RhoA (and its regulators) have been demonstrated
to be critical for normal cytokinesis (28). RhoA is a small
GTPase which functions as a molecular switch in diverse
Figure 3. FLCN and p0071 co-localize and interact at the midbody during telophase/cytokinesis. (A) FTC-133 cells transfected with FLCN were stained for
FLCN, endogenous p0071 and a-tubulin. Enlargements of midbodies are displayed below the original images with only FLCN and p0071 channels displayed.
P0071 and FLCN are concentrated at the midbody (stained with a-tubulin) at cytokinesis. FLCN and p0071 co-localized pixels are displayed in white on the
zoomed images. Manders overlap co-efficient ¼ 0.625. (B) HaCat cells were fixed and stained for FLCN, p0071 and a-tubulin. Both proteins show concentrated
localization at the midbody at endogenous levels. FLCN and p0071 co-localized pixels are displayed in white on the zoomed images. Manders overlap
co-efficient ¼ 0.687. (C) Hela cells were co-expressed with pVen-1-Flag-p0071 and pVen2-HA-FLCN and fixed after 24 h. Cells were stained for HA (to iden-
tify transfected cells) and a-tubulin (to identify cells in the late stages of cytokinesis). Association was detected by BiFC, displaying a focused signal at the
midzone of a telophase cell.
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cellular processes, including cell adhesion, migration and cell
cycle progression (29,30). Previously, p0071 was shown to
regulate Rho activity through a direct association with RhoA
and with Ect2 (a Rho guanine-nucleotide exchange factor
essential for cytokinesis) (19). We found that, in addition to
folliculin co-localizing with p0071 at the midbody, folliculin
deficiency was associated with the deregulation of Rho signal-
ling and cytokinesis defects with significantly increased
numbers of multinucleated cells.
Though folliculin function has not previously been linked to
the cell junctions, we found that folliculin co-localized with
p0071 at cell junctions. Loss of cell polarity and cell–cell ad-
hesion is a frequent feature of epithelial cancers and, while
linked to tissue invasion and metastasis, can also occur early
in tumourigenesis (31). As cancer cell lines may harbour mul-
tiple genetic and epigenetic events that might disrupt epithelial
polarity, we investigated the effects of folliculin inactivation
on epithelial cell polarization in IMCD-3 cells which are
widely used to investigate the physiology of epithelial polar-
ization. We found that the knockdown of FLCN expression
in IMCD-3 cells disrupted the ability of cells to form tight
junctions and was associated with a significant reduction in
trans-epithelial resistance at day 8. This observation, phe-
nocopied the effects of knocking down p0071, consistent
with a functional role for the folliculin/p0071 complex in
the formation of intercellular cell junctions. Consistent with
the TEER results, both FLCN and p0071 knocked down
cells displayed disordered patterns of the Claudin-1 tight junc-
tion protein by immunostaining. p0071 binds classical cadher-
ins through its armadillo repeat region and is believed to
regulated cadherin stability (23). We postulated that as the ad-
hesive activity of E-cadherin is required for the assembly of
tight junctions (32,33), the disruption of Claudin-1 staining
might result from abnormal E-cadherin localization. Both
FLCN and p0071 knocked down cells showed an abnormal
pattern of E-cadherin staining, thus suggesting that both
FLCN and p0071 are required for the formation and mainten-
ance of adherens junctions. This is interesting as loss of
E-cadherin is a frequent finding in epithelial cancers and
loss of the major clear cell, RCC tumour suppressor gene,
Von Hippel-Lindau, is associated with the down-regulation
of E-cadherin expression (34).
In the interphase cell, Rho induces actin cytoskeletal stress
fibres and facilitates cell migration at both the leading edge
and rear of cells (35,36). RhoA is often overexpressed in clin-
ical cancers, and given its role in cell adhesion and migration,
it has been implicated in invasion and metastasis (21). Though
fibrofolliculomas are benign tumours, BHD-associated renal
cancers may metastasise (2,37). We investigated the potential
impact of disordered RhoA signalling associated with follicu-
lin inactivation on the migratory ability of the metastasis-
derived cancer cell line FTC-133. We found that cells not
expressing folliculin migrated significantly more quickly
than folliculin expressing cells in both cell scratch and
Boyden chamber assays. Furthermore, the treatment of
FTC-133 folliculin null cells with Y-27632 (an inhibitor of
ROCK—a downstream effector of Rho) significantly
reduced the migratory phenotype. Previously, the inhibition
of ROCK was shown to reduce cancer cell motility in vivo
(38) and our findings suggest a novel potential therapeutic
Figure 4. Loss of FLCN induces the deregulation of RhoA signalling. (A) Three BHD cell models were tested for levels of RhoA. RhoA levels significantly
increased in FTC133 cells (FLCN-negative) compared with FLCN re-expressing clone. In both renal cell models Hek293 and kidney cancer cell line (ACHN),
transient and stable FLCN knockdown, respectively, caused an increase in RhoA levels. (B) GTP bound (active) RhoA is increased in FLCN null cells (FTC-133)
compared with FLCN re-expressing cells (2-fold). Results normalized to FLCN expressing FTC-133 cells (n ¼ 3). (C) Active RhoA is increased in ACHN
cells with stable FLCN knockdown (30% increase). Repeats normalized to the activation of ACHN scrambled control (n ¼ 3).
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approach to the treatment of metastatic BHD tumours with
deregulated Rho signalling.
The investigation of rare familial forms of kidney cancer
can (as exemplified by Von Hippel–Lindau disease) provide
important insights into the pathogenesis of more common
forms of kidney cancer (39). To date, the functions of the
BHD syndrome gene product folliculin have been relatively
poorly characterized. Through identifying a novel folliculin-
binding partner, we have linked folliculin inactivation to loss
of epithelial cell polarity and normal intercellular junction for-
mation, disordered cytokinesis and dysregulated RhoA signal-
ling and so provided novel insights into the mechanisms of
folliculin tumour suppressor activity. Furthermore, the cellular
consequences of the folliculin/p0071 complex inactivation are
germane to the pathogenesis of many human cancers.
MATERIALS AND METHODS
DNA constructs, antibodies and RNA interference
Human FLCN cloned into the pFLAG-CMV vector (Sigma-
Aldrich, St Louis, MO, USA) has been described previously
(40). p0071 cloned into pDSRed-N1 has been described previ-
ously (19).
For BiFC analysis, the p0071 vectors [p.Ven1-Flag-p0071
wild-type (WT), p.Ven1-Flag-p0071-Rep] have been
described previously (19). FLCN was cloned into the corre-
sponding Venus 2 plasmid to form a fusion of FLCN tagged
with HA to the N-terminus of Venus 2 (p.Ven-HA-FLCN).
Monoclonal antibodies used for immunoprecipitation and
western blotting include FLCN (Rabbit mAb Cell Signalling),
p0071 (Mouse mAb, Progen Biotechnik, Heidelberg, Germany),
RhoA (Mouse mAb, Abcam, Cambridge, UK), Flag (monoclo-
nal ANTI-FLAG M2, Sigma-Aldrich) and b-actin (mouse
monoclonal, Sigma-Aldrich).
Antibodies used for immunofluorescence microscopy ana-
lysis include FLCN (Rabbit mAb Cell Signalling), p0071
(Guinea Pig antibody), Flag (M2, Sigma-Aldrich), HA
(rabbit polyclonal, Rockland) and a-tubulin (mouse monoclo-
nal, Sigma-Aldrich)]. Rabbit polyclonal antibodies against
ZO-1 and claudin-1 and a mouse monoclonal antibody
against E-cadherin were from Invitrogen.
siRNA sequences were purchased from Applied Biosys-
tems. The human FLCN siRNA sequence was GGAAG
GUGGCAUUCAGAUG. The mouse FLCN siRNA sequence
was CCUCAGCAAGUAUGAG, and mouse p0071 sequence
was CAGACAGCAUUGUAUCGC.
Yeast two-hybrid screen
The yeast two-hybrid assay was conducted at the DFKZ
Cancer Research Centre, using a human foetal brain library
as a source of prey.
Cell lines and culture conditions
The thyroid carcinoma cell line FTC-133 harbours an FLCN
inactivating mutation and does not express WT FLCN and
so was used to determine the effects of folliculin in an isogenic
background. FTC-133 cells stably transfected with FLCN or
empty vector have been described previously (41). FTC-133
cells were maintained in 50% Dulbecco’s modified Eagle’s
medium and 50% Ham’s F12, supplemented with 0.5 mg/ml
G418 solution (PAA, Pasching, Austria). To confirm the
effects of folliculin deficiency in another cell line, we used
ACHN renal carcinoma cells with stable knockdown of
FLCN (by shRNA) and a stable, scrambled control that were
kindly donated by Professor Arnim Pause (McGill University,
Montreal, Canada) and have been described in Hudon et al.
(15). These cells were grown in 100% Dulbecco’s modified
Eagle medium (DMEM) supplemented with 1 mg/ml puro-
mycin. Three cell lines (MCF-7, HaCat and Hela cells) that
were most appropriate for high-resolution imaging studies
were investigated. IMCD-3 cells were used to investigate the
effects of folliculin on cell junction formation as the other
cell lines are derived from cancers and may harbour multiple
mutations in cell adhesion protein genes. MCF-7, HaCat and
Hela cells were grown in 100% DMEM (PAA) and Hek293
and IMCD-3 in 100% DMEM, all without selective antibiotic.
IMCD-3 cells were plated and grown on 0.4 mm-pore Transwell
permeable supports (Corning), at 1 × 105 cells per well to allow
polarization of cells.
All cell culture reagents were purchased from Sigma-
Aldrich unless otherwise stated.
Figure 5. Reintroduction of FLCN rescues the multinucleation phenotype in
FTC-133 cells. (A) Representative images of FLCN+/2 FTC-133 cells
stained with tubulin and DAPI. (B) Graph of percentage of multinucleated
cells in FTC-133 vector expressing and FLCN expressing cells (P , 0.01; at
least 400 cells counted from at least three independent experiments). Error
bars represent the SD.
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Figure 6. FTC-133 cells lacking FLCN are more migratory due to increased RhoA signalling. A serum-starved monolayer of confluent FTC-133 cells was
scratched with a sterile pipette and left to migrate for 96 h. (A) Graph displaying % of scratch healed every 24 h for FLCN re-expressing FTC-133 cells
(red line) and FTC-133 empty vector expressing cells (blue line). (B) Graph displaying % of scratch healed for FTC-133 empty vector expressing cells
treated with a 12 h, 10 mM dose of Y27632 (Rock inhibitor; green line) compared with the same cells treated with water control (blue line). Error bars represent
the standard deviation calculated from three-independent experiments. (C) Representative pictures of migrations at 0, 48 and 96 h after scratching. (D) Folliculin
expressing cells migrate significantly more slowly through a porous membrane towards a chemotactic stimulus than those expressing empty vector (P ¼ 0.02).
Treatment of FTC-133 cells (no FLCN expressed) with Y27632, significantly reduces migratory ability (P ¼ 0.007). In neither assay was there a significant effect
of Y27632 treatment on cells expressing folliculin (data not shown). Significance tested by independent t-tests from three independent experiments and error bars
represent the SD.
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Protein extraction
Cells were grown in either 100 mM dishes or 6-well
plates, washed with phosphate buffered saline and scraped
into cell lysis buffer [Tris, pH 7.4, NaCl 150 mM, ethylenedia-
minetetraacetic acid (EDTA) 0.5 mM, 1% Triton] containing
protease inhibitors (Roche Applied Sciences). Lysates were
centrifuged (at 13 300 × g, 48C for 20 min) and levels of total
Figure 7. Cell junctional defects in IMCD-3 cells with reduced FLCN or p0071. Cells were seeded onto transwell supports to induce cell polarization. (A)
Knockdown of FLCN and p0071 was confirmed by quantitative real-time polymerase chain reaction (PCR). (B) There is a significantly reduced TEER in
cells depleted of FLCN or p0071 at day 8 (P , 0.005). (C) There is reduced expression of both E-cadherin and claudin-1 at cell junctions in cells treated
with FLCN or p0071 siRNA.
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cellular protein determined using the DC protein assay kit
according to the manufacturer’s instructions (Bio-Rad Laborator-
ies, Ltd).
Co-immunoprecipitation
For co-immunoprecipitation, 4 mg of antibody was covalently
conjugated to 20 ml of Dynabeads Protein G (Invitrogen) using
triethanolamine and dimethyl pilimidate (except in the case of
anti-FLCN in which case 0.5 mg was used). For semi-
exogenous, co-immunoprecipitation 200 mg and endogenous
co-immunoprecipitation 250 mg of the total cellular protein
was incubated with 20 ml of antibody-bound Dynabeads at
48C for 3 h. The complexes were washed three times with
lysis buffer [Tris, pH 7.4, NaCl 300 mM, EDTA 0.5mM, 1%
Triton X-100, protease inhibitor cocktail (Roche)]. Pulled
down proteins were eluted by boiling in 2× sample buffer,
Laemmi (Sigma-Aldrich) and loaded onto 8% SDS–PAGE
gels.
Protein blotting
For immunoblotting, eluted protein (co-immunoprecipitate) or
15–25 mg of the extracted total cellular protein were separated
using 8% SDS–PAGE gels (for p0071 and FLCN) or 12.5%
gels for all other proteins. For primary antibody details, see
above. Secondary antibodies were purchased from Dako, and
signal detected using the enhanced chemiluminescence
(ECL, Amersham) western blot analysis system.
Immunofluorescence microscopy analysis
Primary antibodies used for immunofluorescence are given
above. Cells were cultured on poly-L-lysine-coated glass
coverslips, fixed with 3.7% formaldehyde at 48C and
permeablized with 0.5% Triton X-100. Secondary antibodies
were Cy-3-coupled anti-rabbit, anti-mouse and anti-guinea
pig (The Jackson Laboratory), Dylight 649 anti-mouse and
anti-rabbit, Dylight 488 anti-mouse and anti-guinea Pig
(Dianova). DNA was stained with 4′,6-diamidino-2-phenylin-
dole (DAPI) (Invitrogen-Molecular probes). Images were
taken with either a Nikon Eclipse 600 or a Zeiss, Axio Obser-
ver .Z1 microscope with ApoTome.
BiFC analysis
Hela cells were co-transfected with pVen1-Flag-p0071 and
p.Ven2-HA-FLCN using a calcium precipitation transfection
procedure. Twenty-four hours after transfection, yellow fluor-
escence of the cells (indicative of interaction between the pro-
teins and reconstitution of YFP) was detected and imaged
using a Nikon Eclipse 600 microscope. Cells were also
stained for HA (using anti HA-rabbit) and Flag (anti-Flag
mouse) to identify co-transfected cells.
G-LISA RhoA activation assay
To measure the levels of GTP-bound (active) RhoA, the
G-LISA activation assay was used (Cytoskeleton, Inc.). The
assay uses a 96-well plate, with a specific Rho-GTP-binding
protein linked to each well. Active RhoA in cell lysates bind
to the well of the G-LISA plate, while the inactive RhoA
(GDP bound) is removed by washing. The bound active
RhoA is then detected with a RhoA-specific antibody and a
horseradish peroxidase conjugated secondary antibody. After
the addition of a detection reagent, the levels of RhoA activity
were measured using a Victor X3 Multilabel plate reader
(PerkinElmer) detecting absorbance at 490 nm.
Figure 8. FLCN knockdown disrupts cell polarization in a three-dimensional culture. IMCD3 cells treated with either FLCN or control siRNA were grown in the
Geltrex matrix. The cells with FLCN knockdown did not form a normal lumen and formed multilayered structures in 49 of 100 structures (compared with 9 of
100 in the control knockdown cells; Fisher’s exact test, P , 0.0001).
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Cell migration assays
Cell migration was assayed using in vitro cell-scratch migra-
tion assays and transwell migration assays. Briefly, folliculin
expressing FTC-133 cells and FTC-133 cells expressing an
empty vector were grown to full confluency in 6-well plates.
Cells were starved of serum overnight and a scratch introduced
using a p200 pipette tip (and also a perpendicular scratch for
reference). Cells were treated with either 10 mM Y-27632
(Rock inhibitor) or distilled water control (media changed
every 12 h). Images of the scratch were captured at 0 h and
every 24 h until the scratch was healed. The percentage of
scratch healed was determined from the images using
ImageJ software (http://rsb.info.nih.gov/ij/). Experiments
were carried out in triplicate.
Effects of folliculin expression and Y-27632 treatment on
chemotaxis were tested using the CytoSelectTM 24-Well Cell
Migration Assay kit from Cell Biolabs according to the man-
ufacturer’s protocol. FTC-133 cells expressing folliculin or an
empty vector (6 × 104 per assay), and treated with either
10 mM Y-27632 or ddH2O, were serum starved for 2 h and
then seeded, in serum-free media, into an upper chamber,
and were left for 18 h to migrate towards serum-positive
media (10% FBS) in the lower chamber. Migratory abilities
were quantified with a Perkin Elmer VICTORTM X3 fluores-
cence plate reader at 480/520 nm.
Real-time quantitative PCR analysis
Quantitative TaqMan PCR was used to confirm FLCN and
p0071 knockdown in IMCD3 cells. mRNA was extracted
from cell pellets using the TRIzol Plus RNA Purification Kit
(Ambion), and cDNA synthesized. TaqMan gene expression
assays for murine p0071 and FLCN were purchased from
Applied Biosystems.
Trans-epithelial resistance assay and investigation
of cell polarization defects
IMCD3 cells were treated with either p0071, FLCN or
Luciferase siRNA and seeded onto Transwell supports.
TEER was measured after 8 days using an EVOM AC
square wave current resistance meter (World Precision
Instruments).
At day 8, filters were mounted between coverslips and fixed
with 4% formaldehyde. Cells were stained for E-cadherin,
claudin-1 and ZO-1 to assess junctional formation and were
visualized using a Leica SP5 Laser Scanning Confocal Micro-
scope.
For three-dimensional culture of cells, IMCD3 cells were
treated with siRNA to either FLCN or luciferase (control)
and were grown in 2% Geltrex (Invitrogen) for 4 days at
378C. Cells were then fixed and stained for E-cadherin and
claudin-1 and were visualized by Confocal microscope. One
hundred cell colonies were counted for both control and
FLCN knockdown with the absence of a lumen and multi-
layered structures noted, and significance tested by Fisher’s
exact test.
Statistical methods
Error bars displayed represent the standard deviation. Statistic-
al significance was determined by comparing data from at
least three independent experiments, using the Student’s
t-test unless otherwise stated. Probability values are located
in corresponding figure legends.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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